Remember me
Figure 1. Algorithm for study participants enrollment and the risk of hepatitis B reactivation in various conditions. CTx, chemotherapy; HBV, hepatitis B virus; ICI, immune checkpoint inhibitor; NUC, nuceos(t)ide analogues; TKI, tyrosine kinase inhibitor.
Figure 1. Algorithm for study participants enrollment and the risk of hepatitis B reactivation in various conditions. CTx, chemotherapy; HBV, hepatitis B virus; ICI, immune checkpoint inhibitor; NUC, nuceos(t)ide analogues; TKI, tyrosine kinase inhibitor.
Figure 2. (A) Cumulative incidence of HBV reactivation in HBsAg-positive patients without prophylactic NUC who received chemotherapy or tyrosine kinase inhibitor (TKI). (B) Comparison of cumulative HBV-related hepatitis incidence between HBsAg-positive patients without prophylactic NUC receiving chemotherapy and TKI. (C) Comparison of cumulative HBV reactivation incidence in patients receiving first-line TKI without prophylactic NUC between HBsAg-positive and HBsAg-negative groups. TKI, tyrosine kinase inhibitor.
Table 1. Clinical characteristics of the included patients. N/A, not available; TKI, tyrosine kinase inhibitor.
Table 1. Clinical characteristics of the included patients. N/A, not available; TKI, tyrosine kinase inhibitor.
N = 1960Age, years (range)63.0 (55.0–71.0)Gender, n (%) Male1176 (60.0%) Female784 (40.0%)Smoking, n (%) No955 (48.7%) Yes847 (43.2%) N/A158 (8.1%)Stage, n (%) I165 (8.4%) II85 (4.3%) III349 (17.8%) IV1361 (69.4%)Histology, n (%) Squamous cell carcinoma245 (12.5%) Adenocarcinoma1423 (72.6%) Small cell carcinoma133 (6.8%) Others159 (8.1%)First-line treatment, n (%) Chemotherapy1284 (65.5%) Tyrosine kinase inhibitor (TKI)Table 2. Clinical data of patients developing HBV reactivation after systemic anticancer treatment. 3TC, lamivudine; ALT, alanine aminotransferase; ASP8273, an EGFR TKI; ETV, entecavir; LdT, telbivudine; TAF, tenofovir alafenamide; TKI, tyrosine kinase inhibitor. # The treatment duration in patients receiving first-line TKI only was counted since the initiation of TKI, while those receiving chemotherapy with previous TKI treatment was counted since the initiation of chemotherapy. $ HBV reactivation without HBV-related hepatitis. @ HBV prophylaxis before chemotherapy.
Table 2. Clinical data of patients developing HBV reactivation after systemic anticancer treatment. 3TC, lamivudine; ALT, alanine aminotransferase; ASP8273, an EGFR TKI; ETV, entecavir; LdT, telbivudine; TAF, tenofovir alafenamide; TKI, tyrosine kinase inhibitor. # The treatment duration in patients receiving first-line TKI only was counted since the initiation of TKI, while those receiving chemotherapy with previous TKI treatment was counted since the initiation of chemotherapy. $ HBV reactivation without HBV-related hepatitis. @ HBV prophylaxis before chemotherapy.
Patient No.Baseline CharacteristicsAntineoplastic TreatmentHBV ReactivationAge/SexHBsAgALT (U/L)Medication CoursesDuration #Table 3. Univariate and multivariable analysis for HBV reactivation in lung cancer patients receiving tyrosine kinase inhibitor treatment only.
Table 3. Univariate and multivariable analysis for HBV reactivation in lung cancer patients receiving tyrosine kinase inhibitor treatment only.
VariableTotalUnivariate AnalysisMultivariable Analysis n = 349Hazard Ratio (95% CI)p ValueHazard Ratio (95% CI)p ValueAge 0.96 (0.92–1.00)0.0670.97 (0.93–1.01)0.164Gender Female204Reference Reference Male1451.63 (0.61–4.35)0.3271.18 (0.35–3.97)0.792Smoking habit Never smoker244Reference Reference Ever smoker752.04 (0.74–5.62)0.1672.73 (0.72–10.32)0.140Tyrosine kinase inhibitor Gefitinib85Reference Reference Erlotinib1410.52 (0.17–1.62)0.2620.32 (0.10–1.04)0.059 Afatinib770.43 (0.11–1.74)0.2390.33 (0.08–1.42)0.135 Osimertinib230.56 (0.07–4.70)0.5960.35 (0.04–3.42)0.365HBV serology Negative HBsAg276Reference Reference Positive HBsAg7362.20 (8.21–471.08)<0.00153.77 (7.00–412.90)<0.001
Comments (0)